CAS Insight

molecules of the month


oral, CNS-penetrant splicing modulator w/ HTT activity

in Ph. II for Huntington's (prev. SMA)

further characterization of SMA candidate

Nat. Commun.

Novartis, Cambridge, MA

oral, CNS-penetrant splicing modulator w/ HTT activity - Novartis, Cambridge, MA
3 mins read

Context. Branaplam (Novartis Institutes for Biomedical Research) is an oral brain-penetrant splicing modulator, originally developed as a small molecule splicing modulator for spinal muscular atrophy (SMA). It turns out to also lower huntingtin levels and is being developed (with Fast Track Designation) for patients with Huntington’s Disease which is driven by mutant huntingtin prion. It is expected that treatments that reduce levels of the toxic mutant huntingtin protein (mHTT) in the brain will slow progression of the disease. Current treatments only target symptoms of the disease, while the more effective therapeutic modalities such as antisense oligonucleotides and RNAis which focus on lowering mHTT levels require delivery techniques that are not ideal in clinical settings. These challenges make an agent such…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: